A novel preventive strategy against HIV-1 infection: combinatorial use of inhibitors targeting the nucleocapsid and fusion proteins
Open Access
- 15 January 2017
- journal article
- Published by Taylor & Francis Ltd in Emerging Microbes & Infections
- Vol. 6 (1), 1-8
- https://doi.org/10.1038/emi.2017.26
Abstract
The strategy of simultaneously attacking multiple targets is worthy of exploration in the field of microbicide development to combat HIV-1 sequence diversity and minimize the transmission of resistant variants. A combination of S-acyl-2-mercaptobenzamide thioester-10 (SAMT10), an inhibitor of the HIV-1 nucleocapsid protein (NCp7), and the fusion inhibitor sifuvirtide (SFT) may exert synergistic effects, since SFT can block viral fusion at an early stage of the viral cycle and SAMT10 can disrupt viral particles at a later stage. In this study, we investigated the effect of the combination of SAMT10 and SFT on HIV-1 infection using in vitro cell culture and ex vivo mucosal explant models. A range of doses for each compound was tested at 10-fold serial dilutions based on their 50% effective concentrations (EC50). We observed a synergistic effect of SAMT10 and SFT in vitro against both the laboratory-adapted HIV-1 strain HIV-1IIIB (subtype B, X4) and three pseudotyped viruses prevalent in Chinese sexually tra...Keywords
This publication has 32 references indexed in Scilit:
- Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidatesAIDS, 2016
- A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02)AIDS Research and Human Retroviruses, 2015
- Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and TenofovirThe Journal of Infectious Diseases, 2015
- A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study)PLOS ONE, 2015
- Development of HIV-1 Rectal-Specific Microbicides and Colonic Tissue EvaluationPLOS ONE, 2014
- A Phase 1 Randomized, Double Blind, Placebo Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel (MTN-007)PLOS ONE, 2013
- Colorectal microbicide designAIDS, 2011
- Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in WomenScience, 2010
- Reverse Transcriptase Inhibitors as Potential Colorectal MicrobicidesAntimicrobial Agents and Chemotherapy, 2009
- Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusionNature, 2005